Abstract: Methods and apparatus to perform process placement for distributed applications are disclosed. An example method comprises determining a mapping between a communication graph representative of communications of a distributed application and a topology graph representative of communication costs associated with a computing network, and executing the distributed application with the processes of the distributed application assigned to the processing entities of the computing network based upon the mapping.

Abstract: Methods and apparatus to provide techniques for planners that records constraints over a set of numeric state variables for each fact and characterizes the set of states in which that fact is true to provide more information to reason about mutual exclusions among sets of states offering a tighter bound on the metric cost of a plan than existing planners currently attain. This more accurate estimate can avoid irrelevant states and decrease search times.

Abstract: Method and apparatus for an adversarial planner to create a first plan for a first agent and a second plan for a second agent, wherein the first and second plans are independent, identify conflicts between the first and second plans, and address the identified conflicts by planning a contingency branch for one of the agents that resolves the conflict in the agent's favor, and splicing that new branch into the agent's plan.

Abstract: A method of correcting and detecting errors in a sector of data stored in a DVD format is provided. The method includes: calculating an initial error detection value for data within the sector, performing an error correction operation on the data within the sector and determining an updated, intermediate error detection value responsive to the error correction operation, using a target error detection value and one of the initial error detection value and the intermediate error detection value to determine that the sector doesn't include errors, processing an outer code to provide a set of error patterns and error locations, and determining if any of the error locations are for data within the sector and not correcting data corresponding to the error locations within the sector.

Abstract: A semiconductor structure includes a semiconductor substrate of a first conductivity type; a pre-high-voltage well (pre-HVW) in the semiconductor substrate, wherein the pre-HVW is of a second conductivity type opposite the first conductivity type; a high-voltage well (HVW) over the pre-HVW, wherein the HVW is of the second conductivity type; a field ring in the HVW and occupying a top portion of the HVW, wherein the field ring is of the first conductivity type; an insulation region over and in contact with the field ring and a portion of the HVW; a gate electrode partially over the insulation region; a drain region in the HVW, wherein the drain region is of the second conductivity type; and wherein the HVW horizontally extends further toward the drain region than the pre-HVW; and a source region adjacent to, and on an opposite side of the gate electrode than the drain region.

Abstract: This invention relates to a pendulum assembly within a laser levelling apparatus. In use, the assembly is rotatably mounted with the levelling device to hang under the effect of gravity such that opposed light emitting devices produce light on a horizontal plane. The assembly includes a main body rotatably mountable in the levelling apparatus and at least two light emitting devices mounted in or on light emitting mounting portions. At least one of the light emitting mounting positions is rotatably mounted to the main body and adjustable in its orientation with respect to the main body by an threaded adjustment means. Once one light emitting device is mounted, the adjustable one can be brought into a substantially co-linear position by movement of the threaded adjustment means. A further embodiment includes a further light emitter acting on a reflective surface to provide a substantially vertical light.

Abstract: This specification discloses a packet type arbitrator in a wireless local area network (WLAN) and its arbitrating method. The arbitrator contains at least two packet type detectors and a packet type decider. The packet type detector is installed with a false alarm checking module and a timer according to the strength of the packet for delaying the decision from the packet type decider. Through the checking mechanism of the false alarm checking module and the timer, erroneous decision can be avoided when determining the packet type.

Abstract: Pharmaceutical formulations and methods are provided for the sustained delivery of a pharmaceutical agent to a patient by injection. The injectable formulation includes porous microparticles which comprise a pharmaceutical agent and a matrix material, wherein upon injection of the formulation a therapeutically or prophylactically effective amount of the pharmaceutical agent is released from the microparticles for at least 24 hours. A method for making the injectable, sustained release pharmaceutical formulation may include dissolving a hydrophobic matrix material in a volatile solvent to form a first solution; adding a pharmaceutical agent to the first solution to form an emulsion, suspension, or second solution; and removing the volatile solvent from the emulsion, suspension, or second solution to yield porous microparticles which comprise the pharmaceutical agent dispersed, entrapped or encapsulated within the structure of the hydrophobic matrix material.

Abstract: A method is provided for making a parenteral dosage form of a pharmaceutical agent which includes (a) providing particles of a pharmaceutical agent; (b) blending the particles with particles of at least one bulking agent to form a first powder blend, which does not include a surfactant; (c) milling the first powder blend to form a milled blend which comprises microparticles or nanoparticles of the pharmaceutical agent; and (d) reconstituting the milled blend with a liquid vehicle, which includes at least one surfactant, for parenteral administration. A method also is provided which includes (a) providing particles of a pharmaceutical agent; (b) blending these particles with particles of an excipient to form a first blend; and (c) milling the first blend to form a milled blend that includes microparticles or nanoparticles, which exhibits a greater dispersibility, wettability, and suspendability as compared to the particles of step (a) or the first blend.

Abstract: Dry powder pharmaceutical formulations for pulmonary or nasal administration are made to provide an improved respired dose. These formulations may be blends of milled blends and may include a phospholipid, alone or in combination with other excipient materials. In one case, the process includes the steps of (a) providing particles which comprise a pharmaceutical agent, (b) blending the particles with particles of at least one first excipient to form a first powder blend; (c) milling the first powder blend to form a milled blend which comprises microparticles or nanoparticles of the pharmaceutical agent; and (d) blending the milled blend with particles of a second excipient to form a blended dry powder blend pharmaceutical formulation suitable for pulmonary or nasal administration.

Abstract: A method is provided for making an oral dosage form of a pharmaceutical agent which includes the steps of (a) providing particles which include a pharmaceutical agent; (b) blending the particles with particles of a pre-processed excipient to form a primary blend, wherein the pre-processed excipient is prepared by (i) dissolving a bulking agent (e.g., a sugar) and at least one non-friable excipient (e.g., a waxy or liquid surfactant) in a solvent to form an excipient solution, and (ii) removing the solvent from the excipient solution to form the pre-processed excipient in dry powder form; (c) milling the primary blend to form a milled pharmaceutical formulation blend that includes microparticles or nanoparticles of the pharmaceutical agent; and (d) processing the milled pharmaceutical formulation blend into a solid oral dosage form or liquid suspension for oral administration. The process yields formulations having improved wettability or dispersibility.

Abstract: Methods and apparatus to provide techniques for planners that records constraints over a set of numeric state variables for each fact and characterizes the set of states in which that fact is true to provide more information to reason about mutual exclusions among sets of states offering a tighter bound on the metric cost of a plan than existing planners currently attain. This more accurate estimate can avoid irrelevant states and decrease search times.

Abstract: Methods and apparatus to incorporate user feedback during planning. In one embodiment, first and second plans are generated for which user feedback is obtained and used to generate a revised plan.

Abstract: This invention relates to unique variant forms of HIF-1 alpha polypeptide that are stable under hypoxic and nonhypoxic conditions and their use in the treatment of disorders involving oxygen homeostasis.

Abstract: A planner generates a plan having actions based upon domain and problem definition information provided by a user. The planner stores a rationale for decisions made for each one of the series of actions. A user can query the planner to retrieve rationale information from an action. A user can modify and/or add constraints to the plan and the planner can generate a new plan using a portion of the plan affected by the new constraints.

Abstract: Methods are provided for making a dry powder blend pharmaceutical formulation comprising (i) forming microparticles which comprise a pharmaceutical agent; (ii) providing at least one excipient in the form of particles having a volume average diameter that is greater than the volume average diameter of the microparticles; (iii) blending the microparticles with the excipient to form a powder blend; and (iv) jet milling the powder blend to deagglomerate at least a portion of any of the microparticles which have agglomerated, while substantially maintaining the size and morphology of the individual microparticles. Jet milling advantageously can eliminate the need for more complicated wet deagglomeration processes, can lower residual moisture and solvent levels in the microparticles (which leads to better stability and handling properties for dry powder formulations), and can improve wettability, suspendability, and content uniformity of dry powder blend formulations.

Abstract: Methods are provided for making a dry powder blend pharmaceutical formulation comprising (i) forming microparticles which comprise a pharmaceutical agent; (ii) providing at least one excipient in the form of particles having a volume average diameter that is greater than the volume average diameter of the microparticles; (iii) blending the microparticles with the excipient to form a powder blend; and (iv) jet milling the powder blend to deagglomerate at least a portion of any of the microparticles which have agglomerated, while substantially maintaining the size and morphology of the individual microparticles. Jet milling advantageously can eliminate the need for more complicated wet deagglomeration processes, can lower residual moisture and solvent levels in the microparticles (which leads to better stability and handling properties for dry powder formulations), and can improve wettability, suspendability, and content uniformity of dry powder blend formulations.

Abstract: This specification discloses a packet type arbitrator in a wireless local area network (WLAN) and its arbitrating method. The arbitrator contains at least two packet type detectors and a packet type decider. The packet type detector is installed with a false alarm checking module and a timer according to the strength of the packet for delaying the decision from the packet type decider. Through the checking mechanism of the false alarm checking module and the timer, erroneous decision can be avoided when determining the packet type.

Abstract: Methods are provided for making a dry powder blend pharmaceutical formulation, comprising the steps of: (a) providing microparticles which comprise a pharmaceutical agent; (b) blending the microparticles with at least one excipient in the form of particles to form a powder blend; and (c) jet milling the powder blend to form a dry powder blend pharmaceutical formulation having improved dispersibility, suspendability, or wettability as compared to the microparticles of step (a) or the powder blend of step (b). The method can further include dispersing the dry powder blend pharmaceutical formulation in a liquid pharmaceutically acceptable vehicle to make an formulation suitable for injection. Alternatively, the method can further include processing the dry powder blend pharmaceutical formulation into a solid oral dosage form. In one embodiment, the microparticles of step (a) are formed by a solvent precipitation or crystallization process.

Abstract: Pharmaceutical formulations and methods are provided for the sustained delivery of a pharmaceutical agent to a patient by injection, by oral administration or by topical administration. The injectable formulation includes porous microparticles which comprise a pharmaceutical agent and a matrix material, wherein upon injection of the formulation a therapeutically or prophylactically effective amount of the pharmaceutical agent is released from the microparticles for at least 24 hours. The oral formulation includes porous microparticles which comprise a pharmaceutical agent and a matrix material, wherein a therapeutically or prophylactically effective amount of the pharmaceutical agent is released from the microparticles for at least 2 hours following oral administration.